NCT03406962View on ClinicalTrials.gov

MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 9, 2018

Primary Completion Date

February 10, 2020

Study Completion Date

January 15, 2021

Conditions
Inherited Metabolic Disorders (IMD)
Interventions
DRUG

MGTA-456

Hematopoietic stem cell transplantation will be done with the cell therapy product MGTA-456.

Trial Locations (2)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

55455

University of Minnesota, Minneapolis

Sponsors
All Listed Sponsors
lead

Magenta Therapeutics, Inc.

INDUSTRY